Background. Aerococcus urinae is an emerging urinary pathogen frequently identified by MALDI-TOF. It is generally susceptible to β-lactams, however, its susceptibility pattern to fluoroquinolones (FQ) remains variable. The goals of this study were (i) to evaluate the performance of the gradient diffusion method (Etest ® ) to determine FQ resistance compared with broth microdilution (BMD) and (ii) to estimate the resistance rate of A. urinae toward FQ in Quebec hospitals.
BMD readings were often complicated by noticeably poor growth. The categorical agreement of the Etest ® was 83% for ciprofloxacin and 95% for levofloxacin. Four very major errors were identified in a preliminary manner on 11% (4/35) of the ciprofloxacin-resistant isolates and 11%(4/35) of the levofloxacin-resistant isolates. Agar dilution will be done to confirm these results.
Conclusion. In our experience, the method recommended by the CLSI for A. urinae susceptibility testing of FQ presented several problems, including insufficient growth and difficult reading. The Etest ® appears to be a promising method for susceptibility testing of FQ for urinary tract isolates, but will first require a further comparison with agar dilution methods. In our study, the rate of FQ non-susceptibility of A. urinae was 27% for levofloxacin and 33% for ciprofloxacin. October 6, 2018: 12:30 PM Background. Ventilator-associated pneumonia (VAP) is one of the most commonly encountered hospital-acquired infections worldwide, and one of the major contributors to an over mortality in critically ill patients. Initial empirical antimicrobial therapy is often broad-spectrum. Fast identification and quantification of microorganisms is of great importance to enable early effective targeted antimicrobial treatment. This trial compares the performance of the new BioFire ® Pneumonia Panel (BPP) with quantitative conventional culture (CC) and an independent real-time quantitative molecular-based method (MM), in Intensive Care Unit (ICU) patients with VAP suspicion.
Methods. Bronchoalveolar lavage (BAL) specimens from 120 patients with suspected VAP, enrolled at four different French ICUs, during January to November 2013, were analysed by CC, following microbiological standard procedures, by BPP and MM. A total of 15 bacterial targets, commonly detected by the three methods, were analysed for concordance above an agreed threshold for positivity. While every step is fully integrated, from specimen-to-results (BPP), bacterial DNA was extracted from each sample on the NucliSENS easyMAG® Platform, and real-time polymerase chain reactions were run in an ABI 7500 Dx thermocycler (MM).
Results. A total of 117 different BAL specimens were processed. Positive culture was obtained for 65.8% of BAL, while positive detections were observed in 79.4% with BPP and 75.4% with independent MM. Fourteen different species were detected by the three methods, with majority of the bacteria being S. aureus, P. aeruginosa, and H. influenzae. Overall concordance performance between BPP and CC was 89.0% (83.1%-94.9%) positive percentage agreement (PPA) and 95.9% (95.0%-96.9%) negative percentage agreement (NPA). Overall concordance between BPP and MM was 97.1% (93.8%-100.3%) PPA and 96.6% (95.6%-97.6%) NPA. Following discrepancy analyses overall performance increased to 95.3% (91.2-99.3%) PPA when comparing BPP to CC. Background. There are limited data on routine use of anaerobic blood cultures and the prevalence of patients with anaerobic bacteremia in Thailand.
Conclusion. The new
Methods. Thammasat University Hospital is a 650-bed university hospital located in central Thailand. We implemented routine blood culture work up for adults using paired aerobic/anaerobic bottles using the BACTEC FX system (BD Diagnostics) as a standard practice. Gram stain and inoculation of positive blood cultures on aerobic and anaerobic culture media were performed and maintained in anaerobic conditions by the Anoxomat™ system (Mart Microbiology). Vitek2 system (BioMerieux) was used for bacterial identification. Data on positive blood cultures, bacterial identification, and time to positivity (TTP) between aerobic and anaerobic bottles were compared. Characteristics of patients with bacteremia were reviewed.
Results. During December 2016-October 2017, 323 blood culture sets were processed (one BACTEC anaerobic Plus bottle and two aerobic bottles). Majority of samples received were from patients hospitalized in an intensive care unit (surgical ICU 28% and medical ICU 25%) followed by general medical unit (19%) and surgical unit (16%). There were 21 positive cultures from anaerobic bottles (21/323, 6.5%) vs. 30 positive cultures from aerobic bottle (30/646, 4.6%) (P = 0.3). Bacteria isolated from anaerobic bottles included Staphylococcus aureus (n = 8), coagulase-negative staphylococci (n = 3), viridans group streptococci (n = 1), Klebsiella pneumoniae (n = 8), and Escherichia coli (n = 1). Positivity rate of Gram-positive bacteria (GP) from anaerobic bottle was slightly higher than the rate of GP from aerobic bottle (12/203, 3.1% vs. 12/646, 1.9%; P = 0.08) There was no isolation of anaerobic bacteria. TTP from anaerobic bottles (mean of 15.6 hours, range 11-26 hours) was significantly faster than TTP from aerobic bottles (mean of 49.5 hours, range 13-100 hours) (P <0.001). The majority of the positive samples were from patients hospitalized in an ICU (16/21, 76.2%), especially in a surgical ICU (13/21, 61.9%).
Conclusion. Our population had a low prevalence of anaerobic bacteremia. The anaerobic bottle significantly decreased the TTP compared with an aerobic bottle. The cost-effectiveness of routinely including an anaerobic blood culture bottle needs further study.
Disclosures. Background. Staphylococcus aureus (SA) is a major human pathogen, causing a variety of nosocomial and community-acquired infections. Nasal carriers of SA are at increased risk for healthcare associated infections with this organism. Timely detection of SA and Methicillin-resistant Staphylococcus aureus (MRSA) and decolonization of pre-surgical patients carrying SA are of importance in infection prevention. We sought to evaluate the clinical performance of the Xpert SA Nasal Complete assay (Xpert SA) for detection of SA and MRSA in the nasal specimens from pediatric patients.
Methods. A total of 504 nasal specimens were collected in the Copan dual swab systems from patients with ages between 0 to 61 years with 91.9% patients ≤21 yearold (n = 463). For each sample, one swab was tested with Xpert SA. The second swab was plated onto Blood agar, Mannitol salt agar and ChromID™ MRSA plate and incubated at 35°C in non-CO 2 incubator. The identification of SA and MRSA was compared
